Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report

A 69-year-old man with refractory lung adenocarcinoma was treated with gemcitabine and vinorelbine. Dyspnea and hypertension developed after the 17th cycle of chemotherapy. Laboratory findings revealed intravascular hemolysis and renal dysfunction. Thrombotic microangiopathy (TMA) was confirmed by r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuribayashi, Tadahiro, Fujiwara, Keiichi, Onishi, Kiriko, Mitsumune, Sho, Takigawa, Yuki, Watanabe, Hiromi, Kudo, Kenichiro, Sato, Akiko, Sato, Ken, Kitagawa, Masashi, Ota, Kosuke, Shinno, Yoko, Shibayama, Takuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740084/
https://www.ncbi.nlm.nih.gov/pubmed/35082630
http://dx.doi.org/10.1159/000520484
Descripción
Sumario:A 69-year-old man with refractory lung adenocarcinoma was treated with gemcitabine and vinorelbine. Dyspnea and hypertension developed after the 17th cycle of chemotherapy. Laboratory findings revealed intravascular hemolysis and renal dysfunction. Thrombotic microangiopathy (TMA) was confirmed by renal biopsy. Antihypertensive and steroid therapies were ineffective. After plasmapheresis, intravascular hemolysis and renal dysfunction gradually improved. However, the disease progressed, and he died 6 months after TMA diagnosis. Autopsy revealed similar pathological findings to those of the renal biopsy. It is important to discontinue gemcitabine at the onset of TMA and consider TMA when using gemcitabine for long periods.

Ejemplares similares